Additional European Equity News - 24th August 2026

This is a routine daily research-sheet compilation rather than a single market-moving event, and the three items sit in different buckets that historically trade very differently. The Evolution buyback disclosure is housekeeping: share repurchase programme updates of this kind are mechanically supportive at the margin but rarely re-rate a stock on their own, with the more telling signal historically being the pace of execution relative to the authorised envelope and free float. The GSK item is the most consequential of the set: a first global approval for a hepatitis B therapy extends the commercial footprint of an already marketed asset class, and in comparable episodes the market read has hinged less on the approval itself than on peak-sales assumptions and the size of the addressable patient population in the approving market. The Metso bolt-on follows the standard Nordic industrial playbook of small, portfolio-filling acquisitions in adjacent pump technology, a pattern that has typically been absorbed as neutral-to-modestly-positive unless it signals a shift in capital allocation strategy away from buybacks or dividends. None of the three is the kind of print that moves an index; the follow-ons worth noting are sell-side revisions on GSK's pipeline assumptions and any further Metso deal flow.